1Di Ieva A, Gaetani P, Giannini M, et al. Oligodendroglial gliomatosis cerebri. Case report. J Neurosurg Sci ,2006,50 : 123-125.
2Gregory T,Armstrong PCP, Lucy B. et al. Gliomatosis cerebri:20 years of experience at the Children' s Hospital of Philadelphia. Cancer,2006, 107 : 1597-1606.
3Sawaya R, Hammoud M, Schoppa D, et al. Neurosurgical outcomes in a modem series of 400 craniotomies for treatment of parenchymal tumors [J]. Neurosurgery, 1998, (5) 42:1044-1045.
4Siangprasertkij C, Navalitloha Y. A multivariate analysis of patients with glioma: a treatment outcome and prognostic factor for survival [J]. J Med Assoc Thai, 2008, (4) 91:491-496.
5Hulshof MC, Koot RW, Schimmel EC, et al. Prognostic factors in glioblastoma ultiforme [J]. Strahlenther Onkol. 2001, (6) 2: 283-290.
6Pollack IF, Campbell JW, Hamilton RL, et al. Proliferation index as a predictor of prognosis in malignant gliomas of childhood [J]. Cancer, 1997,79:(4): 849-856.
7Winger M J, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in aduhs. The prognostic importance of extent of resection and prior low-grade glioma [J]. J Neurosurg. 1989. (4) 71:487-493.
8Veelen ML, Avezaat C J J, Kros JM, et al. Supertentorial low grade ast rocytoma: Prognostic factors, dedifferentiation, and the issue of early versus late surgery [J]. J Neurol Neurosurg Psychiatry, 1998,(5)64: 581-587.
9Jeremic B, Milicic B, Grujicic D, et al. Multivariate analysis of clinical prognostic factors in patients with glioblastoma muhiforme treated with a combined modality approach [J]. J Cancer Res Clin Oncol., 2003,129(8) : 477-484.
10Van den Bent MJ, Chinot O, Boogerd W, et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972[J]. Ann Oncol,2003, 14(4): 599-602.
